Biohaven Ltd. to Post FY2023 Earnings of ($4.92) Per Share, Cantor Fitzgerald Forecasts (NYSE:BHVN)

Posted by Defense World Staff on Apr 9th, 2023

Biohaven Ltd. (NYSE:BHVN – Get Rating) – Research analysts at Cantor Fitzgerald issued their FY2023 earnings per share estimates for Biohaven in a research report issued on Tuesday, April 4th. Cantor Fitzgerald analyst C. Duncan anticipates that the company will post earnings of ($4.92) per share for the year. Cantor Fitzgerald currently has a “Overweight” rating and a $31.00 target price on the stock. The consensus estimate for Biohaven’s current full-year earnings is ($5.08) per share.

BHVN has been the subject of several other reports. SVB Securities began coverage on shares of Biohaven in a research report on Tuesday, January 24th. They issued an “outperform” rating and a $24.00 price target for the company. SVB Leerink reaffirmed an “outperform” rating and set a $24.00 target price on shares of Biohaven in a research report on Tuesday, January 24th. Finally, JPMorgan Chase & Co. assumed coverage on Biohaven in a research report on Wednesday, January 4th. They issued an “overweight” rating and a $23.00 price target on the stock. Two investment analysts have rated the stock with a hold rating and six have given a buy rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $38.39.

Biohaven Price Performance

Shares of NYSE BHVN opened at $12.84 on Friday. Biohaven has a 1 year low of $5.54 and a 1 year high of $20.57. The firm has a market cap of $875.84 million, a PE ratio of -0.90 and a beta of 1.04. The company has a 50 day simple moving average of $15.29 and a 200 day simple moving average of $23.63.

Institutional Investors Weigh In On Biohaven

Several institutional investors and hedge funds have recently made changes to their positions in the business. US Bancorp DE lifted its stake in Biohaven by 19.1% in the first quarter. US Bancorp DE now owns 586 shares of the company’s stock valued at $70,000 after buying an additional 94 shares during the period. Cetera Advisor Networks LLC acquired a new stake in Biohaven in the first quarter worth $332,000. AlphaCrest Capital Management LLC bought a new stake in Biohaven in the first quarter valued at $344,000. BlackRock Inc. raised its holdings in shares of Biohaven by 0.5% during the first quarter. BlackRock Inc. now owns 4,656,866 shares of the company’s stock valued at $552,163,000 after purchasing an additional 21,586 shares during the period. Finally, Dimensional Fund Advisors LP boosted its position in shares of Biohaven by 55.3% during the 1st quarter. Dimensional Fund Advisors LP now owns 82,599 shares of the company’s stock worth $9,794,000 after purchasing an additional 29,413 shares in the last quarter. Institutional investors own 98.01% of the company’s stock.

About Biohaven

(Get Rating)

Biohaven Ltd., a clinical-stage biopharmaceutical company, focuses on discovering and developing therapies for patients with debilitating neurological and neuropsychiatric diseases in the United States. The company's pipeline products include BHV-7000, a potassium channel activator for the treatment of focal epilepsy; Troriluzole, a tripeptide prodrug that is in Phase 3 clinical trial for the treatment of neurological and neuropsychiatric illnesses; BHV-5500, a low-trapping glutamate N-methyl-D-aspartate receptor antagonist for neuropathic pain; and Verdiperstat, an irreversible myeloperoxidase enzyme inhibitor for the treatment of neurodegenerative diseases.